Investigational drug · Phase 3
Fenebrutinib
Also called: RO7010939, GDC-0853, G02599853
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
18
Any phase or sponsor naming "Fenebrutinib"
First trial start
2020
Oct 26, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fenebrutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsing Multiple Sclerosis
- Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Fenebrutinib" as an intervention, largest first.
- A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)Pivotal-lookingNot yet recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07937852 · 1,800 participants (planned) · Start Jan 18, 2027 · Primary completion Nov 30, 2029
Drug: Fenebrutinib · For: Multiple Sclerosis
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04544449 · 985 participants · Start Oct 26, 2020 · Primary completion Sep 17, 2025
Drug: Fenebrutinib; Ocrelizumab and 2 more · For: Multiple Sclerosis, Primary Progressive
Sites: Homewood, Alabama; Berkeley, California; Fullerton, California · 190 sites in all
- Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04586023 · 751 participants · Start Mar 24, 2021 · Primary completion Sep 5, 2025
Drug: Fenebrutinib; Teriflunomide and 1 more · For: Relapsing Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Torrance, California · 106 sites in all
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04586010 · 746 participants · Start Mar 17, 2021 · Primary completion Jan 27, 2026
Drug: Fenebrutinib; Teriflunomide and 1 more · For: Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Homewood, Alabama; Phoenix, Arizona · 158 sites in all
- Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02833350 · 578 participants · Start Sep 9, 2016 · Primary completion Jul 2, 2018
Drug: GDC-0853; Adalimumab and 3 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Glendale, Arizona; Covina, California · 150 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02983227 · 496 participants · Start Nov 30, 2016 · Primary completion Jul 17, 2019
Drug: GDC-0853 · For: Rheumatoid Arthritis
Sites: Glendale, Arizona; Covina, California; El Cajon, California · 104 sites in all
- A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02908100 · 260 participants · Start Jan 19, 2017 · Primary completion May 28, 2019
Drug: GDC-0853; Placebo · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Los Alamitos, California; Boca Raton, Florida · 70 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03407482 · 160 participants · Start Jan 9, 2018 · Primary completion Nov 20, 2019
Drug: GDC-0853 · For: Lupus Erythematosus, Systemic
Sites: Los Alamitos, California; Boca Raton, Florida; Brandon, Florida · 53 sites in all
- A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03137069 · 134 participants · Start May 26, 2017 · Primary completion Sep 27, 2019
Drug: GDC-0853; Placebo · For: Urticaria
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 27 sites in all
- A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05119569 · 109 participants · Start Mar 1, 2022 · Primary completion Mar 29, 2023
Drug: Fenebrutinib; Placebo · For: Relapsing Multiple Sclerosis
Sites: Fullerton, California; Las Vegas, Nevada; Banja Luka, Bosnia and Herzegovina · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.
Centonze D, Calabrese M, Cocco E, et al. · Neurol Ther 2026
- Efficacy of disease-modifying therapies in primary progressive multiple sclerosis: systematic review and network meta-analysis.
Reyes-de-la-Mata Y, Cano-Martinez G, Alegre-Del-Rey EJ, et al. · Mult Scler Relat Disord 2026
- Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials.
Joerg L, Stolyar J, McGovern J, et al. · J Drugs Dermatol 2026
- Phase II and III biologics and small molecules for chronic spontaneous urticaria: A systematic review.
Kadu P, Huang CA, Ulfers A, et al. · Dermatol Online J 2026
- Utilization of Brain Physiologically Based Pharmacokinetic Modeling in Support of CNS Drug Development: Case Example of Fenebrutinib.
Bowman CM, Ma F, Xu Y, et al. · AAPS J 2026
- Emerging pharmacotherapies for chronic spontaneous urticaria: spotlight on BTK inhibitors.
Karstarli Bakay OS, Kocatürk E · Expert Opin Pharmacother 2026
Also in development for Relapsing Multiple Sclerosis
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- TolebrutinibSAR442168Phase 33 trials
Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.